IP Verse

Patent Oppositions in pain and inflammation drugs industry

Explore the competitive field of pain and inflammation drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in pain and inflammation drugs technology and learn how to protect your intellectual property.

Top companies filing patent oppositions

Explore the top companies that have filed the most patent oppositions in the technology industry.

Last updated on: Aug 27, 2026
CompanyTotal Oppositions
NUTRICIA8
SANDOZ7
STRAWMAN6
TEVA PHARMACEUTICAL INDUSTRIES LTD6
GENERICS UK5
HAMPTON KNOWLES4
FRESENIUS KABI DEUTSCHLAND4
HOFFMANN EITLE4
POLPHARMA3
JAMES POOLE3

Top companies facing patent oppositions

Explore the top companies that have faced the most patent oppositions in the technology industry.

Last updated on: Aug 27, 2026
CompanyTotal Oppositions
AMGEN EUROPE20
THE UNITED STATES OF AMERICA12
BOEHRINGER INGELHEIM11
CELGENE9
ARENA PHARMACEUTICALS6
CJ BIOSCIENCE6
ABBOTT LABORATORIES6
D PHARMA RESEARCH6
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG6
BEONE MEDICINES I5

Top active law firms filing patent oppositions

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Last updated on: Aug 27, 2026
Law FirmTotal Oppositions Filed
ELKINGTON AND FIFE13
TER MEER STEINMEISTER & PARTNER GBR8
D YOUNG7
HOFFMANN EITLE7
KRAUS & LEDERER PARTGMBB6
NEDERLANDSCH OCTROOIBUREAU5
CARPMAELS & RANSFORD5
HAMM&WITTKOPP PATENTANWÄLTE PARTMBB5
FRESENIUS KABI DEUTSCHLAND4
BIRD & BIRD3

Latest patents opposed in the pain and inflammation drugs industry

Patent challenges are becoming increasingly common in the pain and inflammation drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the pain and inflammation drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
EP4387968
Crystal Forms Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-CarboxamideBRISTOL MYERS SQUIBBAug 11, 2026HAMPTON KNOWLES
EP3500575
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEONE MEDICINES IAug 5, 2026HAMPTON KNOWLES
EP3500575
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEONE MEDICINES IAug 4, 2026DEVA HOLDING
EP3917493
Topical Gel Compositions Of NaproxenBAYER HEALTHCAREAug 4, 2026STRAWMAN
EP3500575
Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENEAug 3, 2026SANDOZ
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEMay 20, 2026SANDOZ
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEMay 19, 2026SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEMay 13, 2026DEVA HOLDING
EP3799885
Neutralization Of Inhibitory Pathways In LymphocytesINNATE PHARMAMay 13, 2026STRAWMAN
EP3756650
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPEMar 18, 2026COOKE

Top patents facing oppositions in pain and inflammation drugs industry

To stay ahead in the competitive pain and inflammation drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the pain and inflammation drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Aug 27, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
EP3078667
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
EP3756650
Aug 20, 2025Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneAMGEN EUROPE11
EP2223688
May 29, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE6
EP2397142
Jul 27, 2022Use Of Dpp Iv InhibitorsBOEHRINGER INGELHEIM PHARMA GMBH & CO. KG6
EP3241550
Jul 22, 2020(1R, 2R)-3-(Dimenthyl Amino-1-Ethyl-2-Methyl-Propyl) Phenol For Treating Painful InflammationsGRNENTHAL5
EP3500575
Feb 25, 2026Crystalline Form Of (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetra-Hydropyrazolo[1,5-A]Pyrimidine-3-Carboxamide, Preparation, And Uses ThereofBEIGENE5
EP3242666
Dec 25, 2024Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALS4
EP2797581
May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-DioneCELGENE3
EP3209381
Nov 14, 2018Compositions Comprising Bacterial StrainsCJ BIOSCIENCE3
EP2658399
Feb 28, 2024Nutritional Compositions Comprising Human Milk Oligosaccharides And Nucleotides And Uses Thereof For Treating And/Or Preventing Enteric Viral InfectionABBOTT LABORATORIES3